Navigation Links
New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine

three doses of either GARDASIL or placebo at day one, month two and month six. The primary analyses of these trials evaluated the efficacy of GARDASIL compared to placebo in women who were free of infection with the relevant HPV types (6, 11, 16 and/or 18) when they started the study, remained free of infection with the relevant HPV types through month seven, received all three doses of GARDASIL within one year and had no protocol violations.

FUTURE I was designed to evaluate the impact of GARDASIL on the incidence of cervical lesions and pre-cancers (CIN 1-3), vulvar and vaginal external lesions and pre-cancers (VIN 1-3 and VaIN 1-3) and external genital warts caused by the four HPV types targeted by the vaccine (HPV 6, 11, 16 and 18). FUTURE II was designed to evaluate the impact of GARDASIL on pre-cancers and non-invasive cancers (CIN 2/3, AIS) caused by HPV 16 and 18. Prevention of advanced, or high grade cervical pre-cancerous lesions -- CIN 2/3 or AIS -- has been identified by the FDA and World Health Organization as the most meaningful indicator of cancer efficacy for a cervical cancer vaccine.

Results showed that GARDASIL provided significant protection in women not previously exposed to HPV types targeted by the vaccine

In FUTURE I, after an average follow-up of three years, GARDASIL provided 100 percent protection from HPV 6-, 11-, 16- and 18-related VIN 1-3, VaIN 1-3 and genital warts; no cases were observed in the vaccine group (n=2,261) compared to 60 cases in the placebo group (n=2,279). GARDASIL was also 100 percent effective for the prevention of HPV 6-, 11-, 16-, or 18-related CIN 1-3; there were no cases observed in the vaccine group (n=2,241) compared to 65 cases in the placebo group (n=2,258).

In FUTURE II, after an average follow-up of three years, GARDASIL was 98 percent effective in preventing high-grade cervical pre-cancers associated with HPV types 16 and 18; one case of CIN 3 was observed in the vaccine group (n
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... Mass. , July 10, 2014 Decision ... report awareness of the U.S. Food and Drug Administration,s ... new phosphate binder Velphoro, which was approved by the ... in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... The Medical Oncology Association of Southern California ... an agreement to work together to expand use ... costs of cancer care in Southern California. ... and distribution services to help health care professionals, ...
... The American Society of Bariatric Physicians (ASBP) is sad ... go out to his family, friends and fans.  The recent ... a contributing factor to his death are concerning and bring ... prescribed. While the specific details of Bubba ...
Cached Medicine Technology:Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 2Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 3Physicians Who Treat Obesity Respond to the News of Bubba Smith's Overdose 2
(Date:7/11/2014)... repaired knee Anterior Cruciate Ligament (ACL) happens all too ... the American Orthopaedic Society for Sports Medicine,s (AOSSM) Annual ... risk factors may minimize the chance of a future ... few risk factors such as, age, activity level and ... of re-injury," said lead author, Christopher C. Kaeding, MD ...
(Date:7/11/2014)... July 11, 2014 With the maturity ... requirements on comfort, the installation rate of Chinese car ... the installation rate exceeded 88% and the demand outnumbered ... the next few years, Chinese car electric window regulator ... 2017, the market size is expected to exceed 110 ...
(Date:7/11/2014)... Wild by Nature, a natural and organic supermarket ... opening a fifth store to be located in West Islip, ... the largest selections of wheat and gluten-free products available. With ... stores have become a one-stop shop for anyone who needs ... gluten intolerance, is a spectrum of disorders, including celiac disease, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 B. E. Smith, ... providers, has been retained to lead a national chief ... in Bend, Ore. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... St. Charles Health System is the largest provider of medical ...
(Date:7/11/2014)... the experienced dressmaker in the world, has become one ... to beach wedding dresses . Recently, the firm ... in its online shop. Included in the new range ... has been considered as one of the best garment ... spokesman, BellasDress provides superb special occasion gowns and great ...
Breaking Medicine News(10 mins):Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 2Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 3Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 4Health News:Wild by Nature Opens New Location 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 3Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2
... to treat kidney cancer also targets a genetic mutation active ... (AML), the most common and lethal form of adult leukemia, ... Center report in the Jan. 29 edition of the Journal ... clinical trial, the drug sorafenib reduced the median percentage of ...
... Enforce PROTONIX Patent -, MADISON, N.J., Jan. 29 ... Nycomed, today announced the U.S. launch of Wyeth,s,own generic ... of generic pantoprazole tablets in the U.S. by Teva ... version of PROTONIX,will be distributed by Prasco starting today., ...
... Funding for Bioscience Summer Internship Program Over ... ... Foundation today,awarded $6.5 million to the Translational Genomics Research Institute,(TGen) as ... TGen for the next 25 years. The program helps cultivate new,scientific ...
... 29 At an Election Day,candidate forum in Tampa, ... Mitt Romney told a crowd of the,organization,s conservative seniors ... Hillarycare is not the answer., "I am convinced ... issue and,get our citizens insured but do it in ...
... Nektar,Therapeutics, (Nasdaq: NKTR ) President and Chief ... the upcoming Merrill Lynch,Pharmaceutical, Biotechnology & Medical Device Conference ... on Tuesday, February 5, 2008 at 1:00 p.m.,ET., ... a live,audio-only Webcast through a link posted on the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... it will be participating in Merrill Lynch,s 19th ... New York on,February 5, 2008, at 8:00 a.m. ... presentation can be accessed via Zimmer,s,Investor Relations website ...
Cached Medicine News:Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 2Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 3Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 2Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 2Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 4
... Operation: , Double Burst : 2 60-ms bursts of ... s (1 pulse/s) , Tetanus: 50 Hz (50 ... Single (4 pulses/2 s) , Output Current: Adjustable from ... pulses (200-us duration) , Indicators: Battery LED (green) indicates ...
... of Operation: , Standby: A standby switch maintains ... , Twitch: 1 s (1 pulse/s) , ... (4 pulses/2 s) , Output Current: Adjustable from ... Monophasic pulses (200-us duration) , Indicators: Battery LED ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
... the newest peripheral nerve stimulator from B. Braun ... stimulators providing advanced digital technology. , ,Your ... HNS11 allows the localization of practically all mixed ... ,An additional optional component for the HNS11 ...
Medicine Products: